Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: RXGOLF who wrote (15200)	2/17/1998 5:12:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

RXGOLF, I have had trouble keeping up myself. BioCentury came out with an article on LGND today, and I'm still trying to catch up with the Bear Stearns report as well as how soon clinicals will be out on the rat breast cancer area. This morning's BioCentury report described LGND's dilemma of have two treatments (oral and topical Panretin) for the same disease (KS). Of course, LGND will probably have the same situation soon with CTCL (oral and topical Targretin). The article did provide details on the slow accrual for Panretin oral for APL. In the US, LGND only had 18 out of 182 patients enrolled for the Phase III study. The had used a research group for Phase II and accrual went well, but the group wasn't participating in the Phase III study and the accrual rate was extremely slow. In Europe the incidence in Southern Europe is somewhat higher and the Phase II study only requires 10 patients. Phase III is for 112 patients, but accrual should be faster. However, treatment is changing (current protocols call for combination treatment using a retinoid with chemotherapy), so LGND's European protocol has been changed to reflect this modified approach.